Wave Life Sciences Ltd.NASDAQ: WVE

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

· Issued by Wave Life Sciences Ltd. via GlobeNewswire

Summary by 6ix AI

Wave Life Sciences Ltd., a clinical-stage biotechnology company working on RNA medicines, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review its second quarter 2026 financial results and provide business updates.

Key details

  • The webcast and call can be reached through the Investor Events page in the investors section of the Wave Life Sciences website, and an archived version of the webcast will be available there after the live event.
  • Analysts who plan to ask questions during the live call's question-and-answer portion can join through an audio-conferencing link.

6ix AI wrote this summary from the release below and checked it against the release.

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company's second quarter 2026 financial results and provide business updates.

The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

Wave Life Sciences Ltd. on 6ix

Story so far

Earlier from Wave Life Sciences

Later from Wave Life Sciences

All Wave Life Sciences news releases